News tagged with pemetrexed

Pemetrexed

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of Pleural Mesothelioma as well as non-small cell lung cancer.

This text uses material from Wikipedia and is available under the GNU Free Documentation License.

Clinical trials helped one woman's fight against cancer

(HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from ...

Cancer Apr 18, 2013 | not rated yet | 0

Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed

Previous studies have hypothesized that low levels of the enzyme thymidylate synthase (TS) likely mark patients who will benefit from the drug pemetrexed – but results have been inconclusive at best and at times contradictory. ...

Cancer Aug 29, 2012 | not rated yet | 0 |

KRAS gene mutation and amplification status affects sensitivity to antifolate therapy

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical ...

Cancer Apr 04, 2012 | not rated yet | 0

Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 ...

Cancer Sep 30, 2012 | not rated yet | 0

Standard chemotherapy provides higher survival rate than experimental in lung cancer patients

Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...

Cancer Sep 06, 2012 | not rated yet | 0

Lung cancer ALK rearrangement may predict pemetrexed efficacy, study shows

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed (brand name: Alimta) than patients whose cancer did not show ALK translocation, according to research published ...

Cancer Sep 01, 2011 | 1 / 5 (1) | 0

Antifolates show promise against NSCLC subtype

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer ...

Cancer Nov 14, 2011 | not rated yet | 0